Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 4/20 | 0.44 |
| ▸ | PARP1 | P09874 | 4/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.44 |
| ▸ | TDO2 | P48775 | 4/20 | 0.44 |
| ▸ | IDO2 | Q6ZQW0 | 3/20 | 0.44 |
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15836383 | 0.88 | TRPV4 (0.38) | TNKSPARP1TNKS2TDO2IDO2 | |
| SCHEMBL15836373 | 0.84 | SMN1; SMN2 (0.46) | POLBGAAMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL15836410 | 0.82 | MEN1 (0.46) | TNKSPARP1TNKS2DHODHGAA | |
| SCHEMBL15836399 | 0.82 | GAA (0.34) | GAAMAPTSMN1; SMN2 | |
| SCHEMBL15836366 | 0.78 | MAPT (0.58) | GAAMAPTSMN1; SMN2L3MBTL1GLA | |
| SCHEMBL15836395 | 0.78 | TNKS (0.38) | TNKSPARP1TNKS2 | |
| SCHEMBL15836409 | 0.75 | MAPT (0.39) | PARP1TDO2IDO2POLBGAA | |
| SCHEMBL15836418 | 0.74 | PIK3CD (0.35) | — | |
| SCHEMBL15836371 | 0.73 | TNKS (0.40) | TNKSPARP1TNKS2GAAMAPT | |
| SCHEMBL15836370 | 0.73 | GAA (0.30) | GAAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC. | 2016-01-21 | — | — | US | disclosed |
| US-9221795-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9029384-B2 | Phosphatidylinositol 3-kinase inhibitors | Gilead Calistoga, LLC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140371246-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC | 2014-12-18 | — | — | US | disclosed |
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371246-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, PIK3R4, PIK3R5 | TNKS 550/4885PARP1 1220/4885TNKS2 699/4885 |
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | TNKS 603/4885PARP1 1382/4885TNKS2 785/4885 |
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | TNKS 603/4885PARP1 1382/4885TNKS2 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.